ADAR1 Capital Management, LLC filed a Form 4 with the SEC on October 23, 2026, disclosing a purchase of common shares in InMed Pharmaceuticals Inc., listed on NASDAQ as INM.

Key Highlights

  • Transaction date: October 23, 2026, with transaction code "P" (purchase).
  • Shares acquired: 4 common shares of InMed Pharmaceuticals Inc. at a price of $1.32 per share.
  • Post-transaction holdings: 956,584 common shares beneficially owned following the reported transaction, held indirectly.
  • Reporting persons: ADAR1 Capital Management, LLC and Daniel Schneeberger, identified as 10% owners of InMed Pharmaceuticals Inc.
  • Indirect ownership: The securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and are deemed indirectly beneficially owned by ADAR1 Capital Management, LLC and Daniel Schneeberger, its sole manager.
  • Ownership disclaimer: Each reporting person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein, according to the filing.

ADAR1 Capital Management and Daniel Schneeberger Report October 2026 Purchase in InMed Pharmaceuticals

According to the Form 4 filed with the SEC, ADAR1 Capital Management, LLC, along with Daniel Schneeberger as sole manager, reported a purchase of 4 common shares of InMed Pharmaceuticals Inc. (NASDAQ:INM) on October 23, 2026, at a price of $1.32 per share. The filing identifies both ADAR1 Capital Management, LLC and Daniel Schneeberger as 10% owners of the issuer. The transaction is classified under transaction code "P," indicating a purchase in the open market.

The filing discloses that the reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC. As a result, both ADAR1 Capital Management, LLC and Daniel Schneeberger may be deemed to indirectly beneficially own these securities. Following the reported transaction, the total amount of common shares beneficially owned, on an indirect basis, stands at 956,584, according to the filing.

The filing includes a footnote stating that each reporting person "disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any," and that the report "shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise." No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

ADAR1 Capital Management, LLC and Daniel Schneeberger filed a Form 4 reporting the purchase of 4 InMed Pharmaceuticals common shares at $1.32 on October 23, 2026, with post-transaction indirect beneficial ownership of 956,584 shares.